HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
zolimomab aritox
composed of the ricin A chain which is conjugated to monoclonal antibodies that recognize the CD5 antigen; used in preventing & treating graft-vs-host disease; MW 210 kDa
Also Known As:
CD5 Plus; H65-RTA; Orthozyme CD5plus; XZ-CD5; XomaZyme-H65
Networked:
11
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Albumins: 31532
Ricin: 732
zolimomab aritox: 11
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
zolimomab aritox: 11
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
zolimomab aritox: 11
Lectins: 6782
Plant Lectins: 206
Ricin: 732
zolimomab aritox: 11
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
zolimomab aritox: 11
Plant Proteins: 334
Plant Lectins: 206
Type 2 Ribosome Inactivating Proteins: 3
Ricin: 732
zolimomab aritox: 11
Enzymes and Coenzymes: 1
Enzymes: 152586
Hydrolases: 2166
Glycoside Hydrolases: 871
N-Glycosyl Hydrolases: 36
Ribosome Inactivating Proteins: 51
Type 2 Ribosome Inactivating Proteins: 3
Ricin: 732
zolimomab aritox: 11
Related Diseases
1.
Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
09/01/1991 - "
The results from this phase I trial suggest that H65-RTA is an active drug in the treatment of cutaneous T-cell lymphoma.
"
09/01/1991 - "
A phase I trial was therefore conducted in which 14 patients with cutaneous T-cell lymphoma progressive on other therapies were treated with up to three cycles of H65-RTA.
"
09/01/1991 - "
Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma.
"
2.
Rheumatoid Arthritis
05/01/1993 - "
The CD5 Plus Rheumatoid Arthritis Investigators Group.
"
05/01/1993 - "
We treated six patients with active rheumatoid arthritis with one such agent, the murine IgG1 anti-CD5 immunoconjugate CD5 Plus, as part of a multicenter trial.
"
04/01/1994 - "
An immunoconjugate, CD5 Plus, composed of ricin A chain and murine IgG1 anti-CD5 monoclonal antibody is under investigation for treatment of rheumatoid arthritis.
"
3.
Graft vs Host Disease (Graft-Versus-Host Disease)
02/01/1989 - "
A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
"
11/01/1993 - "
Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
"
4.
Body Weight (Weight, Body)
08/01/1996 - "
CD5-Plus or an identical appearing placebo) was administered at a dose of 0.1 mg/kg body weight on each of 14 consecutive days.
"
06/01/1995 - "
Following repeated doses of H65-RTA, the following findings were demonstrated: peripheral edema, decreased body weight, decreased body temperature (monkey only) in addition to a general inflammatory reaction evidenced by changes in hematology, clinical chemistry, and urinalysis parameters.
"
5.
Renal Insufficiency (Renal Failure)
12/01/1995 - "
No patient developed capillary leak syndrome or renal failure from XZ-CD5.
"
Related Drugs and Biologics
1.
Immunoconjugates (Immunoconjugate)
2.
Ricin
3.
Immunoglobulin G (IgG)
4.
Monoclonal Antibodies
5.
Cyclosporine (Ciclosporin)
6.
Prednisone (Sone)
7.
Methotrexate (Mexate)
8.
Immunotoxins (Immunotoxin)
9.
XomaZyme
Related Therapies and Procedures
1.
Therapeutics
2.
Transplantation